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Abstract
The drive to control neglected tropical diseases (NTDs) has had many successes but to reach
defined targets new approaches are required. Over the last decade, NTD control programmes
have benefitted from increased resources, and from effective partnerships and long-term
pharmaceutical donations. Although the NTD agenda is broader than those diseases of para-
sitic aetiology there has been a massive up-scaling of the delivery of medicines to some billion
people annually. Recipients are often the poorest, with the aspiration that NTD programmes
are key to universal health coverage as reflected within the 2030 United Nations sustainable
development goals (SDGs). To reach elimination targets, the community will need to adapt
global events and changing policy environments to ensure programmes are responsive and
can sustain progress towards NTD targets. Innovative thinking embedded within regional
and national health systems is needed. Policy makers, managers and frontline health workers
are the mediators between challenge and change at global and local levels. This paper attempts
to address the challenges to end the chronic pandemic of NTDs and achieve the SDG targets.
It concludes with a conceptual framework that illustrates the interactions between these key
challenges and opportunities and emphasizes the health system as a critical mediator.
Introduction
Neglected tropical diseases (NTDs) are some of the most common infections of poor people in
impoverished communities not only in the poorest low- and middle-income countries
(LMICs) but also in the richer G20 countries (Hotez, 2017). Several of these diseases (lymph-
atic filariasis, onchocerciasis, soil-transmitted helminths, schistosomiasis and trachoma) are
amenable to preventive chemotherapy (PC). With progress in the delivery of treatments,
there are opportunities to transition from control to elimination of these diseases, or to verify
the absence of further transmission as outlined in the World Health Organization (WHO)
2020 NTD roadmap (WHO, 2012). As we approach elimination targets for PC NTDs in
many settings, programmes face numerous challenges that can be grouped into core categories
– biological and technological, political and social, and environmental (Bockarie et al. 2013;
Webster et al. 2014). This paper explores how the health system can become a mediator
between such challenges at the local level and those at the national/international level.
Specifically, we argue how responsive and resilient health systems are essential to reach the
aspiration of the NTD ‘endgame’ as articulated in the sustainable development goals (SDGs).
Global shocks: a disrupting factor for NTD control
Since 2007, a series of global events that span the social, environmental and political, present a
challenging set of circumstances against which health systems, encompassing NTD pro-
grammes, have been required to adapt such as the global financial crisis, increased conflict,
drought and the emergence of terror organizations. These events have induced almost unpre-
cedented migration, creating refugee and displaced persons crises and stressing already weak
and fragile health systems. The impact of such crises was exemplified during the 2014 Ebola
(EVD) epidemic in Liberia, Sierra Leone and Guinea. EVD originated in remote and difficult
to access communities, with complex health-seeking pathways, a weak and poorly resourced
health system, and limited surveillance capacity. In these contexts, the health system faced
an unprecedented challenge given the high case mortality rates and wide-reaching psycho-
social impacts. Diversion of resources to control this EVD epidemic caused a necessary
acute polarization of global and national health systems and focussed attention away from
other chronic problems, such as NTDs. This presented an impediment to NTD control in
the affected regions, specifically in Sierra Leone where significant progress had previously
been made (Hodges et al. 2011; Pose and Rabinowitch, 2014), as well as in Guinea and
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Liberia where successes in onchocerciasis control has led to the
emergence of NTD programmes supported initially by
Non-Governmental Development Organizations (NGDOs)
(Bogus et al. 2016; Thomas et al. 2017). Thus, global and national
shocks frequently become a significant disrupting factor for NTD
control, and create a challenge for the ability of health systems to
respond appropriately to changing population needs, whilst also
supporting the ‘everyday resilience’ that allows for the ongoing
functioning of routine activity, such as immunization and NTD
programme delivery (Gilson et al. 2017).
Changing global dynamics: a need for better control of vectors
Biological shifts that allow for the rapid emergence and potential
spread of vector-borne viruses, are exemplars of another type of
challenge facing the global health community. The emergence
of Zika virus in the Americas in 2016, has emphasized the need
for better surveillance systems and improved awareness of the
risks of vector-borne viruses. The expansion of the Aedes popula-
tions also poses significant threats to the control of dengue and
Chikungunya, as these Aedes transmitted viruses are expanding
their range, for example, into the Gulf Coast States of the USA.
Yellow fever epidemics have also occurred more recently in cen-
tral Africa and Brazil and as a result, the WHO have initiated
an Eliminating Yellow Fever Epidemic (EYE) strategy with the
aim to eliminate such epidemics (WHO, 2017a). Despite such
changing biological dynamics, there have been many historical
successes in vector control dating back to 1904 including the con-
trol of malaria and yellow fever in Panama; malaria in Brazil (with
the “eradication” of Anopheles gambiae); onchocerciasis in West
Africa; control of dengue in Singapore and Cuba; some initial
impact of vector control on Triatome transmission of Chagas’
Disease in the Southern Cone of the Americas; filariasis control
in the Solomon Islands because of indoor residual spraying
(IRS) against malaria vectors (Webber, 1979); and success in fil-
ariasis programmes through vector control using bed-nets in
Nigeria, The Gambia and Zambia (Blackburn et al. 2006; Eigege
et al. 2013; Rebollo et al. 2015; Nsakashalo-Senkwe et al. 2017).
Perhaps the most notable impact of vector control, however, has
been the reduction in malaria morbidity and mortality attributed
to long-lasting insecticide-impregnated bed-nets (LLIN) in
sub-Saharan Africa. An estimated 68% of the decline in malaria
prevalence was attributed to vector control (including IRS)
between 2000 and 2015 (Bhatt et al. 2015; WHO, 2016).
Despite these historic successes, however, and the clear impact
that vector control can have in addressing many global health
challenges, vector control has been side-lined in attempts to con-
trol and eliminate many NTDs. Many elimination targets focus
on a PC strategy with limited recognition that infections are
acquired by insect bites or contact with freshwater snail habitats.
In elimination programmes, transmission control is the key and
too often the opportunity to address transmission has been
underrecognized. The concept of mass drug administration
(MDA) in lymphatic filariasis and onchocerciasis is designed to
reduce the circulating populations of microfilariae to reduce
transmission without vector control; however, the inclusion of
vector control initiatives would greatly enhance the progression
towards the elimination targets (Hollingsworth et al. 2015).
Progress in control of vectors of other parasitic infections, such
as human African trypanosomiasis, i.e. Glossina spp. (Tirados
et al. 2015), Chagas’ Disease (Dias et al. 2002) and visceral leish-
maniasis, phlebotomine sandflies (Coleman et al. 2015), are crit-
ical to the achievement of elimination targets.
While there is no doubt that vector control should be a key pil-
lar of NTD interventions, the challenges of emerging insecticide
resistance in Anopheles populations in Africa, pose a threat to
the continued impact of bed nets and LLINs (Hemingway et al.
2016). Furthermore, there has been limited recognition of the
role of vectors and the need to increase the focus on transmission
control. For example, whilst the WHO roadmap emphasizes the
need for new drugs and diagnostics, as well as revitalized tools
for monitoring and evaluation, demand for additional vector con-
trol tools and approaches has been noticeably absent (WHO,
2012). However, in its third NTD report WHO did highlight
the additional cost of vector control which would be required to
meet some of the control targets for infections such as dengue
(this report was issued prior to the emergence and spread of
Zika virus). More recently, WHO has responded to the increased
threat of vector-borne infections and published a draft Global
Vector Control Response 2017–2030 (WHO, 2017b). This docu-
ment highlights the contributions which vector control has histor-
ically made to public health and links vector control interventions
to the SDGs.
Environmental shifts
Rapid environmental change resulting in a less stable and unpre-
dictable climate has also impacted on NTD epidemiology. These
changes include: deforestation, mineral extraction and exploit-
ation; habitat destruction and desertification; changes in water
resource availability; severe climate change driving major flood
events and landslides (e.g. China, Bangladesh, Sierra Leone);
more frequent droughts (e.g. Africa) with consequences for
food security; and associated threats to livestock husbandry and
animal well-being as traditional agricultural practices create
local conflicts over land and water resources. Environmental shifts
coupled with changing global patterns and human–animal inter-
actions reinforce the need for a ‘one health’ approach. For
example, the World Health Assembly (WHA) resolution of
2013 on NTDs emphasized that the control of zoonotic diseases
as a core NTD strategy whilst the research priorities were identi-
fied to address the major zoonotic diseases – rabies, echinococco-
sis, taeniasis and neurocysticercosis in the WHO NTD portfolio
(WHO, 2015a).
The neglected within the neglected: innovative approaches
required for impact
Thinking beyond preventive chemotherapy diseases
To date, NTD efforts have focused on the up-scaling of PC by
MDA, fuelled by large-scale drug donations. This has posed chal-
lenges for the management of other NTDs, which require inten-
sive disease management (IDM) such as the trypanosomiases,
Buruli ulcer, leprosy and the leishmaniases which have not been
attributed the same level of resources despite their capacity to
be fatal if untreated and the donation of curative drugs. Such
IDM diseases can be more focal in their geographical distribu-
tions and thus present a need for more nuanced and directive
interventions and a need for greater clinical expertise for diagno-
sis and treatment. There are, however, serious deficits in the thera-
peutic armamentarium for IDM diseases, which have led to
continued investment in and advocacy for, this critical cause by
the Drugs for Neglected Diseases initiative (DNDi) (www.dndi.
org) and significant progress has been made in reducing the bur-
den of human African trypanosomiasis and visceral leishmaniasis
(WHO, 2016; Molyneux et al. 2017). However, those who remain
with chronic clinical, and often irreversible symptoms because of
such diseases, urgently require follow-up action and support.
Furthermore, the foundation of the NTD programme through
‘vertically’ implemented MDA (which frequently by-passes health
systems infrastructure) further compounds this challenge, as staff
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working within routine health services often lack clinical knowl-
edge and capacities to be able to diagnose and manage such con-
ditions. In these situations, a health systems as usual response is
insufficient to address complex chronic conditions and innovative
approaches are needed to reach an often diverse sub-set of a
population who are disproportionately affected by significantly
disabling and potentially life-threatening NTDs.
A need for alternative strategies to enhance preventive
chemotherapy mass drug administration
In West and Central Africa, occurrence of lymphatic filariasis and
onchocerciasis in areas of Loa loa endemicity, pose a significant
challenge to elimination goals because of the severe adverse events
(SAEs) associated with the impact of ivermectin on individuals
with high parasitaemias of Loa microfilaria (>30 000 ml−1),
exacerbating risk of encephalopathy (Gardon et al. 1997;
Boussinesq, 2006). Over nearly two decades, extensive studies
have concentrated research approaches on seeking to understand
the pathology of SAEs as well as searching for strategies to identify
individuals at risk, and where lymphatic filariasis is co-endemic,
to define alternative strategies. Such strategies have included the
use of twice-a-year albendazole, supplemented with vector control
(Pion et al. 2017). There has, however, been limited consideration
of alternative approaches by investing in testing the potential of
reducing transmission by the vector Chrysops; if the transmission
of L. loa in areas of high Loa endemicity could be reduced, the
numbers of individuals with high to moderate parasitaemias
would decline, hence the risk of SAEs would be reduced as high
adult worm loads (driven by high levels of transmission) would
also reduce. The neglect of the Chrysops dimension in considering
the ‘Loa problem’ is reflected in the fact that the first review of
Chrysops biology for over 50 years was published in 2017
(Kelly-Hope et al. 2017). This recent review includes suggestions
for implementing vector control, e.g. the use of ‘tiny targets’,
which are widely deployed for Glossina control (Tirados et al.
2015) and could have significant potential for reducing Chrysops
populations. Thus, alternative strategies that prioritize vector con-
trol, as well as new drug distribution mechanisms, are likely to be
essential in addressing more complex NTD scenarios.
Thinking beyond the parasite: addressing long-term
manifestations of NTDs
There has been considerable debate about the burden attributed
to NTDs by the global burden of disease (GBD) studies
(Murray et al. 2012) and the discrepancy between earlier estimates
of burden (Hotez et al. 2014). The estimates by the GBD 2010
attributed some 27 million disability-adjusted life years
(DALYs) to NTDS whilst a study in 2014 (which included the
17 WHO NTDs as well as other NTD conditions) attributed
47.9 million DALYs (Hotez et al. 2014). Calculations of the mor-
tality associated with NTDs according to the GBD gives an annual
mortality of 150 000, a figure which has been challenged
(Molyneux et al. 2017) as deaths from trematode-induced can-
cers, epilepsy (caused by neurocysticercosis) rabies, and snake
bite were not included. The WHO figure of schistosomiasis asso-
ciated deaths in Africa has also been estimated to be 20 times
higher than GBD estimates, as none of the conditions have
been correctly attributed to the NTD group of diseases but
included as injuries, cancers and neurological conditions.
These discrepancies could reflect the impact of interventions
over the past decade but the attribution of the disability weights
and overall mortality of NTDs remains controversial, as disability
weights and prevalence are key drivers in the calculations of
DALYs. Gross underestimates of the prevalence of cutaneous
leishmaniasis (Bailey et al. 2017) exemplifies this problem where
residual scarring of a cured condition is not included, despite
the social and mental health sequelae caused by the condition
(Bailey et al. 2017). The mental health co-morbidities have recently
been identified as being of increased significance as a major and
chronic morbidity (Litt et al. 2012) in many of the NTDs. The
mental health burden estimated for lymphatic filariasis is two to
three times higher than those estimated by the GBD study for
this condition using highly conservative figures. In addition, the
mental health burden which caregivers suffer in the care of chronic
NTD patients has only been assessed in filariasis (Ton et al. 2015).
In the study of DALYs averted for ten major NTDs (de Vlas et al.
2016), impaired cognitive development due to soil-transmitted hel-
minths and schistosomiasis infection, mental health morbidity,
discrimination and stigma due to disfigurement, social exclusion
resulting in poor marital prospects, the impact of catastrophic
health expenditures and economic impact of reduced ability to
work, were not included in the DALYs averted calculations exem-
plifying the need to adopt a more holistic appreciation of the over-
all NTD burden (Litt et al. 2012). Conversely, the apparent absence
of consideration of NTDs by the mental health community as a
cause of and a contribution to global mental health morbidity,
and the need to address the patient and caregiver needs to give
the existence of so many chronic NTD patients, should bring
NTD and mental health communities together (Ferrari et al.
2013). Mental health is already projected to be the largest cause
of Global Disease Burden by 2030, without consideration of the
contribution of NTDs. Including NTDs within these mental health
projections are important and will further elevate the serious com-
parative lack of recognition for both sets of diseases.
Furthermore, where completed, measures of disease associated
morbidity (including mental health and disability) are frequently
quantitatively defined. Given the complexity and multifaceted
manifestations of NTDs at both the individual and community
level, research that allows for more nuanced understandings
from the perspectives of affected individuals is important
(Reidpath et al. 2011). Historically, the limited acknowledgement
of the lifelong morbidity associated with such diseases (Mieras
et al. 2016), has led to the highly medicalized focus of morbidity
measurement and programme implementation, e.g. the need to
restore sight or reduce physical impairment related to NTDs
such as lymphatic filariasis. Currently, the shift within inter-
national NTD policy and programming to recognize the need
for a holistic approach to the control and management of
NTDs through the presentation of strategies for disease manage-
ment, disability and inclusion (DMDI) (Mieras et al. 2016) repre-
sents the opportunity to develop morbidity measures that are
responsive to the needs and experiences of affected populations,
and how they vary by differing axes of inequality, such as age,
gender, stage of disease, experience of disability and whether liv-
ing with one or several NTDs. Only when the complexities of
individual and household realities are understood and measured
in relation to NTDs are the needs of affected populations likely
to be prioritized and addressed.
Harnessing partnerships and political commitments
The importance of partnerships
There are opportunities for holistic multi-sectoral action to sup-
port robust, resilient and responsive health systems responses to
mediate challenges and sustain NTD control. Notably, NTD part-
nerships require financial resources and management time and
the overall financial envelope has not increased; in 2010, the pro-
portion of Official Development Assistance (ODA) committed to
NTD programmes was 0.6% (Liese and Schubert, 2009). Funds
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over the last 7 years have increased despite the higher profile for
NTDs (Liese et al. 2014). However, the diversity of interests and
the numbers of partners involved has expanded significantly
and this reflects the increasing recognition of the importance of
these diseases. In addition, there is an ever more complex partner
and donor landscape both in terms of implementation of disease-
specific approaches and integrated country programmes. A recent
estimate provided by the infontd website (www.infontd.org) has
identified over 2609 projects on NTDs in 113 countries involving
73 different partners.
Disease-specific partnerships have evolved and expanded in
the last decade to provide focal points for endemic country part-
ners, ministries of health, researchers and donors including WHO
and the NGDO community (Liese et al. 2010). Such partnerships
have an important advocacy role and enhance communication,
networking, and technological advancements. The expansion of
NGDO interest in NTDs has seen the development of the
NNN-NGDO/NTD/Network over recent years (www.ntd-ngonet-
work.org), as well as the Coalition for Operational Research
COR-NTD (www.ntdsupport.org/cor-ntd) which identifies and
supports operational research priorities. Research partnerships
that span all areas of the translational research spectrum are
also of critical importance in increasing the adaptability of
NTD programmes in relation to emergent challenges.
Partnerships, however, must be based on parity of esteem of
partners, transparency of management, the capacity to recognize
sensitivities and manage them, regular communication and
adequate resourcing. Most importantly, they should prioritize
equity between colleagues in the global north and global south
and be responsive to the needs and priorities of health systems
and populations in LMICs who face the largest burden of
NTDs. The significance of cross-cutting issues in the control of
NTDs such as links to the WASH sector (WHO, 2015b), educa-
tion, environment, agriculture and livestock, are important prere-
quisites to meeting the United Nations SDGs (Bangert et al.
2017). Partnerships that include expertise across and within
such sectors and prioritize multi-disciplinary and multi-sectoral
action are of critical importance if we are to reach the NTD ‘end-
game’. Below we illustrate the range of strategic partnerships
needed across the translational research continuum: T1 (basic
research), T2 (human/clinical research), T3 (evidence into prac-
tice) and T4 (practice to policy).
Partnerships for drug development (T1–T2)
The anti-Wolbachia (A·WOL) consortium reflects the importance
of building a partnership for drug development using the compara-
tive advantage of academic institutions and industry partners. The
partnership focuses on the development of an effective macrofilar-
icide against adult filaria worms based on the efficacy of antibiotics
against Wolbachia endosymbionts of Onchocerca and Wuchereria
(www.awol.lstmed.ac.uk). Having demonstrated the efficacy of
doxycycline as a macrofilaricide, A·WOL have promising candidate
alternatives which can shorten the duration of treatment needed to
secure adult worm death or permanent sterilization of infection.
Such alternatives include high-dose rifampicin (Aljayyoussi et al.
2017) and a new entity TylAMac™ (Turner et al. 2015).
Partnership for innovation and co-implementation across the
disease programmes (T1–T4)
The Integrated Vector Control Consortium (IVCC) (www.ivcc.
com) is an example of the development of novel new vector con-
trol products which will ensure that vector control successes can
be maintained in the future. IVCC is the only partnership involv-
ing academia, WHO, and the pesticide industry, focused on
seeking alternative products for vector control which contrast to
the several partnerships formed for addressing new drugs and
diagnostics such as DNDi (www.dndi.org), the Medicine for
Malaria Venture (MMV) (www.mmv.org), and the Foundation
for Innovative New Diagnostics (FIND) (www.finddx.org). An
irony upon which it is worth reflecting, is that a single new chem-
ical entity effective against vectors, as synthetic pyrethroids have
been over several decades, will impact on all vectors of infectious
agents. Hence, it could be argued that proportionately more
resources should be devoted to the search for new vector control
products given the extent of pyrethroid resistance (Hemingway
et al. 2016). Targeting vectors will have the most effective impact
on transmission control and contribute proportionately more to
elimination. Hence a ‘pan’ vector control product would have a
potentially greater impact than a drug for one specific condition.
Building on the successes of vector control, the operationaliza-
tion of the strategic partnership between the lymphatic filariasis
and the malaria programme in Nigeria has shown the benefit of
co-implementation through the combined distribution of LLIN.
The key success of this programme was the endorsement in the
policy of a synergistic approach of distribution of MDA and
LLIN (Dean et al. 2016).
Partnerships for Health Systems Strengthening (T3–T4)
COUNTDOWN is a multi-disciplinary health systems implemen-
tation research programme which brings together NTD pro-
grammes and research institutes to address country priorities
and challenges for strengthening NTD programme implementa-
tion. COUNTDOWN research takes place in Ghana, Cameroon,
Nigeria and Liberia. For example, in Nigeria, following a situ-
ational analysis, key challenges were identified in four broad
areas including: (i) co-ordination and collaboration; (ii) financial
and non-financial resource mobilization; (iii) long-term multi-
context community engagement; and (iv) human resources man-
agement and motivation (www.countdownonntds.org). Following
identification of these challenges, COUNTDOWN worked with
the Federal Ministry of Health to develop a holistic implementa-
tion research package and will work with the Federal and State
(Ogun and Kaduna) Ministries of Health to implement a partici-
patory action research cycle to generate innovative approaches for
community engagement with the NTD programme, to ensure a
detailed understanding of resources required for sustainable pro-
gramme delivery. This will include a review of the direct and
opportunity costs in relation to NTD treatment seeking and pro-
vision at the individual and household levels, as well as amongst
programme implementers including community directed distri-
butors (CDDs) and frontline health implementers.
Measures of success in improving health
There has been progress in establishing NTDs as a justifiable
cause for investment, initiating action-oriented partnerships and
establishing a respected ‘brand’ (Molyneux, 2012) with which pol-
icy makers, drug donors and philanthropists were prepared to
align. This has provided an enabling environment to progress
towards the targets established in the WHO Roadmap (WHO,
2012) and drive towards more equitable health interventions.
Efforts have included scientific progress, sustained and high-level
advocacy, commitment by the philanthropic community and
NGDOs to the cause, which embraced not only health but also
poverty alleviation as a development target (Hotez et al. 2009;
Molyneux et al. 2017; Bangert et al. 2017). This has been
enhanced by a consistent message around the role NTDs play
in exacerbating poverty and the value for money provided by
the interventions, some of which are dependent on donated high-
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quality assured products with delivery mechanisms able to reach
those beyond ‘the end of the road’, often through sustained com-
munity commitment. The endorsement by the UN system and its
member states following the inclusion of NTDs within the overall
health targets of the SGDs has emphasized their importance as
impediments to development. This has been highlighted by a
detailed analysis of the impact that NTDs have when the other
SDG targets are considered – improved access to water and sani-
tation, the overarching goal of poverty alleviation, improved food
security and hunger alleviation, women’s empowerment,
improved education, absence of discrimination in disability and
strengthened partnerships – all interplay with the broad NTD
agenda, thereby contributing to the overarching goal of poverty
alleviation (Hotez et al. 2009; Bangert et al. 2017).
The NTD community has also embraced a series of targets for
elimination and control as well as a commitment to the eradication
of Guinea Worm (dracunculiasis) and yaws following the publica-
tion of the WHO Roadmap in 2012. In 2013, the World Health
Assembly (2013) endorsed the first comprehensive NTD
Resolution on NTDs which outlined the five key strategies required
for progress (WHA 66.12) including defining the milestones, link-
ing NTDs to universal health coverage (UHC) and estimating the
costs of NTD programmes through a detailed investment case
(WHO, 2015c). The progress towards these targets is monitored
annually for 10 NTDs through the role of Uniting to Combat
NTDs (www.unitingtocombatntds.org). Details of country progress
are regularly updated by WHO through reports in the WHO
Weekly Epidemiological Record including country by country pro-
gress on annual treatments (WHO). NTDs are markers of poverty
in many settings, including in poor areas and communities of G20
countries which together with Nigeria, have the highest number of
people afflicted by NTDs (Hotez, 2017). Hence progress in their
control, elimination or eradication will be a ‘litmus test’ of progress
in reducing poverty. NTDs as ‘tracers of equity’ can provide an
objective measure of overall progress to SDG goals (Engels, 2016)
and thus implementing NTD strategies is an essential element of
UHC to ‘leave no one behind’.
Making NTDs part of the UHC framing and a key indicator for
SDGs is important; but success means turning rhetoric into action.
Such realization is likely to involve the use of equity frameworks in
programme planning and evaluation and participatory approaches
to programme design and appraisal. These approaches require dis-
aggregation of data by key equity markers such as gender, age, pov-
erty and (dis)ability at all levels of the health system and critically
using this data to ensure more responsive adaptation of planning.
Whilst numbers are useful for identifying bottlenecks to equity,
there is also a need to understand the lived experiences and chal-
lenges that affected individuals, their families, and frontline health
providers (such as community-based drug distributors) face. An
example where progress is being made is through the development
of WHO’s Gender Equity and Rights (GER) toolkit. This toolkit
focuses on embedding GER analysis within routine monitoring
and evaluation activities conducted by an NTD programme. The
process uses routinely collected numerical data around NTD treat-
ment/service provision combined with other equity indicators such
as literacy rates or gender parity indicators to identify locations,
where programme inequities may exist. More detailed, numerical
analysis of indicators is then completed in these areas, before
being complemented with a qualitative exploration of implementer
(NTD programme staff, community drug distributors, frontline
health facility staff) and community experience and perceptions
of the NTD programme. Cumulative analysis of numerical data
and data that captures the voices of affected populations, is then
utilized to develop alternative steps in programme implementation
that will increase programme equity in these areas thus creating an
ongoing participatory cycle.
Harnessing new technologies
The opportunities to advance the NTD cause through the appli-
cation of new technologies has been demonstrated by projects
which have embraced the rapid expansion of cell phone networks
and the reduced costs and availability of smartphones. This is per-
haps best exemplified by the Global Trachoma Mapping Project
(GTMP) which has enabled most rapid up-to-date information
regarding the prevalence and distribution of trachoma globally.
Late 2012 to early 2016 saw surveyors collect and transmit data
from 2.6 million people in 29 countries using Android smart-
phones. The GTMP recorded on the International Trachoma
Initiative database more districts in 3 years than had been
recorded in the previous 12 years, and mapped areas where no
data previously existed because of remoteness, insecurity, insuffi-
cient funding or competing public health priorities (www.sightsa-
vers.org/gtmp/).
A new approach to detecting patients requiring care for
lymphatic filariasis has been developed using the mHealth tool
‘MeasureSMS-Morbidity’ which allows health workers to use cell
phones to record and transmit clinical information using short
message services (SMS) (Mableson et al. 2017) for door-to-door
surveys to obtain data on lymphatic filariasis patients in real-time
(location, sex, age, clinical condition) in Dar-es-Salaam, Tanzania.
This enabled identification, recording and mapping of lymphatic
filariasis patients increases the efficiency of planning appropriate
morbidity management and disability prevention (MMDP) activ-
ities (Mwingira et al. 2017). Similarly, the use of global position-
ing system data loggers is likely to become increasingly important
to understand the movement of individuals and the dynamics of
communities and individual behaviours and consequent trans-
mission ecology (Brant et al. 2018).
Over the last decade the use of remote sensing and satellite
imagery for defining habitat and broader ecological associations
(Kelly-Hope et al. 2012; Thomson et al. 2002; Brito et al. 2017)
projecting areas of transmission risk, and the need for a micro-
mapping overlap stratification approach in Loa endemic areas,
has enabled a better understanding of the interactions of ecology
and epidemiology. Given the widespread availability of datasets
and images of potential importance to the changing disease epi-
demiology and infection dynamics (forest and land cover, rainfall,
altitude, geology), high-resolution imaging methodology is likely to
be a more cost-effective approach to mapping and planning than
ground truthing, given the rapidly changing ecology which drives
the dynamics of transmission of vector-borne infection.
The application of network theory has also been used to
ensure that there is a better understanding of the social behaviour
of communities to enhance the efficiency of MDA (Chami et al.
2013, 2016, 2017). These approaches will enhance the efficiency
of delivery of MDA and increase and sustain higher levels of
adherence. A further potential approach that could be used for
mapping, drug delivery and surveillance is the use of unmanned
aerial vehicles (UAVs) or ‘drones’ (Fornace et al. 2014). UAVs can
collect spatial data and their use in ecological research suggests
they have potential in infectious disease epidemiology and public
health research to provide spatial and temporal data in real-time,
enabling an improved understanding of the interactions between
disease transmission, vector ecology and environment.
Capacity strengthening
Significant progress on NTD capacity strengthening has been
made. With the initial focus to support countries with the largest
burdens of NTDs, a strategy which has ensured some progress
towards increasing treatments in high burden countries (Nigeria,
Ethiopia, Democratic Republic of the Congo, Tanzania and
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Indonesia). Learning materials have been developed and training
courses for national programme managers and district-level
teams have been delivered. At Regional WHO levels, significant
progress has been achieved though region specific or topic-specific
meetings to advocate for a national commitment to NTD capacity
development. Building capacity in research as well as in programme
implementation has also been essential, whilst the African Research
Network for NTDS (www.arntd.org) is a partnership model for
research and a critical step forward in meeting this need. We sum-
marize the needs for capacity strengthening in Table 1.
Fig. 1. The Health System as a mediator between the changing global landscape and the community: Moving towards responsive and resilient health systems to
reach the NTD ‘end game’.
Table 1. The challenges of capacity strengthening
• Decentralizing learning activities from WHO to national institutions to facilitate the process of country adaptation, thus requiring the responsibility for
activities such as quality assurance of laboratories, training courses, disseminating WHO materials and guidelines, ensuring timely drug applications and
strengthening the supply chain.
• Countries should assume an advocacy function to ensure NTDs are central to any health training compatible with regional and specific country needs, and
NTD activities need to be routinely embedded in health service personnel training. Information on new technical developments should be incorporated into
national programmes within timeframes compatible with WHO targets.
• Monitoring, evaluation and surveillance towards verification of elimination are supported by quality assured laboratories and that resources are available for
drug efficacy monitoring, entomological evaluation, safety monitoring, data management services, morbidity management and surgery.
• Training material should benefit from the most efficient means of dissemination using Apps and internet resources and m-health platforms.
• Sub-district and lower levels of the health system need to ensure that there is limited attrition of health staff and community-based health workers to
maintain implementation.
• Engagement with the livestock sector to evaluate the most appropriate approaches to addressing zoonotic NTDs (zNTD) and elaborate the necessary partners
to execute zNTD policies and strategies (WHO, 2015a).
• Recognize the challenges of training for intensified disease management where specific treatment regimens change as new drugs and diagnostics become
available ensuring countries embrace new treatment policies and implement them at the earliest opportunity.
• Ensure that vector control and management are fully engaged, recognizing the particular challenges that countries face with a deficit in requisite skills in
medical entomology, pesticide management, monitoring of insecticide resistance where insecticide resistance poses an ever-increasing threat and new
products and novel approaches need to be introduced.
• Investigate the links and opportunities to engage with the WASH sector to disseminate materials pertinent to NTDs within WASH training programmes.
• Evaluate the curricula in all health training facilities (including medical schools) to ensure the recognition of NTDs as relevant topics for future health
professionals.
• Support NTD programmes to utilize equity frameworks within routine health systems monitoring activities to allow for adaptation of programme delivery that
is shaped by the needs of NTD community implementers and affected populations.
• Recognize that capacity strengthening activities can be mutually enhancing and that skills can be developed, learned and applied in the global north as well
as in the global south.
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Conclusion
This paper has highlighted the challenges faced by the NTD com-
munity in achieving established targets in an ever-changing global
world. Challenges that cut across the themes presented in this
paper can be grouped into the biological and technological (e.g.
the demand for new drugs, diagnostics and alternative vector con-
trol); political (e.g. ensuring prioritization of new and old chal-
lenges) and social and environmental (e.g. responding to global
shocks and thinking beyond the parasite) (Bockarie et al. 2013;
Webster et al. 2014) as shown in Fig. 1, spanning both the global
and local levels.
Health systems ultimately become the mediator between the
changing NTD global landscape and the realities of providing
health care to poor communities. Multi-directional capacity
strengthening, therefore, becomes critical in ensuring progress.
As argued, this involves strategic partnership at different stages
of the translational research continuum, a prioritization of equity
facilitated through ongoing political commitments through the
SDGs, and harnessing new technologies. Ultimately equitable
partnerships for progress facilitated through multi-directional
capacity strengthening are required to both build responsive and
resilient health systems and to reach the NTD ‘endgame’.
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